Co-Authors
This is a "connection" page, showing publications co-authored by Stanley Xu and Annette Langer-Gould.
Connection Strength
4.161
-
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
Score: 0.970
-
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
Score: 0.954
-
Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level. Neurology. 2025 May 27; 104(10):e213607.
Score: 0.911
-
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
Score: 0.844
-
Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness. Int J Infect Dis. 2023 Jan; 126:87-93.
Score: 0.192
-
High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness. Int J Infect Dis. 2022 Dec; 125:184-191.
Score: 0.192
-
The impact of timing of initiating invasive mechanical ventilation in COVID-19-related respiratory failure. J Crit Care. 2023 10; 77:154322.
Score: 0.050
-
The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study. J Hosp Med. 2023 01; 18(1):43-54.
Score: 0.048